GCB-DLBCLs, with the highest curability, which carrying the translocation of BCL-2 and c-MYC genes, resulting in constitutive activation of both genes.14,15 Consequently, repression of NF-κB, c-MYC, and BCL-2 expression have been intensely investigated as potential therapeutic strategy in DLBCL patients. Here, NFKB1 is linked to diffuse large B-cell lymphoma.